This research studies protein in tumor samples from patients with non-small cell lung cancer. Finding specific proteins in tumor tissue samples from patients with cancer may help doctors tell what type of lung cancer a patient has and plan better treatment.
PRIMARY OBJECTIVES: I. To validate a novel 4-protein signature's ability to subtype non-small cell lung cancer (NSCLC) in a treatment-naive, multi-institutional cohort, Cancer and Leukemia Group B (CALGB) 9761. SECONDARY OBJECTIVES: I. To estimate the NSCLC misclassification rate in a multi-institutional clinical-trial setting for stage 1 NSCLC (adenocarcinoma versus squamous cell). OUTLINE: Previously collected tissue samples are analyzed via hematoxylin and eosin (H\&E) staining and immunohistochemistry (IHC).
Study Type
OBSERVATIONAL
Correlative studies
Alliance for Clinical Trials in Oncology
Boston, Massachusetts, United States
Validation of a novel 4-protein signature's ability to subtype NSCLC
Time frame: 1 month
NSCLC misclassification rate
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.